CRT 25 - Two-year outcomes of the Prevail paclitaxel-coated balloon show no difference in clinical outcomes compared to other drug-coated balloons (DCBs), suggesting the Prevail DCB is as effective and safe as other contemporary DCB's in a real-world setting. The Prevail DCB was also associated with lower rates of myocardial infarction in the sub-group analysis of patients who also underwent stent implantation.

Mr Sacharias Von Koch (Lund University Hospital, Lund, SE) sits down to outline the key findings from a retrospective, observational analysis using data from the Swedish coronary angiography and angioplasty registry, which compared the performance of the Prevail paclitaxel-coated balloon to other contemporary DCBs in over 6000 patients. The analysis included an unselected patient population who underwent percutaneous coronary intervention procedures using DCBs in Sweden between 2021 and 2024.

Interview Questions:
1. What is the rationale behind this study?
2. What was the study design, patient population and inclusion criteria?
3. What were the key outcomes?
4. Were there any unexpected findings warranting further investigation?

Recorded remotely from Lund, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.